secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001108205-25-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis gains FDA & EMA support for accelerated approval of emavusertib in PCNSL
------------------------------------------------------------------------------

- FDA and EMA agree TakeAim Lymphoma study may support accelerated approval path for PCNSL.
- Emavusertib granted Orphan Drug Designation for PCNSL in both US and EU.
- In 20 BTKi-experienced PCNSL patients: 6 objective responses, 4 complete responses.
- Q4 2024 net loss $9.6M ($1.25/share); FY2024 net loss $43.4M ($6.88/share).
- Cash $20.0M at Dec 31, 2024; plus $10M from March 2025 offerings funds ops into Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000028/0001108205-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000028/cris-20250331.htm
  HTML page:      https://secwatch.observer/filing/0001108205-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer